Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

BACKGROUND: Strategies of active surveillance (AS) of low‐risk screen‐detected prostate cancer have emerged, because the balance between survival outcomes and quality of life issues when radically treating these malignancies is disputable. Delay before radical treatment caused by active surveillance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2010-03, Vol.116 (5), p.1281-1290
Hauptverfasser:	van den Bergh, Roderick C. N., Steyerberg, Ewout W., Khatami, Ali, Aus, Gunnar, Pihl, Carl Gustaf, Wolters, Tineke, van Leeuwen, Pim J., Roobol, Monique J., Schröder, Fritz H., Hugosson, Jonas
Format:	Artikel
Sprache:	eng
Schlagworte:	active surveillance analysis Biochemistry Biological Biological and medical sciences Biomarkers, Tumor - analysis Cancer expectant management Histopathology Humans Male males Medical sciences methods Middle Aged Nephrology. Urinary tract diseases outcomes pathology prostate cancer Prostate-Specific Antigen Prostate-Specific Antigen - analysis Prostatectomy Prostatectomy - methods Prostatic Neoplasms Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery quality of life radical prostatectomy Risk screening surgery survival Time Factors Treatment Outcome Tumor Markers Tumors Tumors of the urinary system Urinary tract. Prostate gland Urologi och njurmedicin Urology and Nephrology watchful waiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND: Strategies of active surveillance (AS) of low‐risk screen‐detected prostate cancer have emerged, because the balance between survival outcomes and quality of life issues when radically treating these malignancies is disputable. Delay before radical treatment caused by active surveillance may be associated with an impaired chance of curability. METHODS: Men diagnosed with low‐risk (T1c/T2; prostate‐specific antigen [PSA] =
ISSN:	0008-543X 1097-0142 1097-0142
DOI:	10.1002/cncr.24882